Growth Metrics

Moderna (MRNA) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$3.6 billion.

  • Moderna's Net Income towards Common Stockholders fell 1638.46% to -$200.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.1 billion, marking a year-over-year decrease of 40.11%. This contributed to the annual value of -$3.6 billion for FY2024, which is 24.46% up from last year.
  • Moderna's Net Income towards Common Stockholders amounted to -$3.6 billion in FY2024, which was up 24.46% from -$4.7 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Net Income towards Common Stockholders peaked at $12.2 billion during FY2021, and registered a low of -$4.7 billion during FY2023.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$3.6 billion (2024), whereas its average is $29.0 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first surged by 1,733.33% in 2021, then plummeted by 156.37% in 2023.
  • Yearly analysis of 5 years shows Moderna's Net Income towards Common Stockholders stood at -$747.1 million in 2020, then surged by 1,733.33% to $12.2 billion in 2021, then plummeted by 31.47% to $8.4 billion in 2022, then tumbled by 156.37% to -$4.7 billion in 2023, then grew by 24.46% to -$3.6 billion in 2024.